Breast MRI for Neaodjuvant Chemotherapy Response Prediction and Evaluation in Breast Cancer, With Focus on Background Parenchymal Enhancement

University Hospital, Strasbourg, France1 site in 1 country100 target enrollmentJanuary 1, 2018

ConditionsBreast Cancer

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Breast Cancer
Sponsor: University Hospital, Strasbourg, France
Enrollment: 100
Locations: 1
Primary Endpoint: Presence or absence of of pathologic enhancement of breast by MRI
Last Updated: 7 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The aim of this retrospective study is to evaluate the value of pre-treatment and post-treatment multimodality MRI study, including quantitative evaluation of background parenchymal enhancement, for response prediction and evaluation. This study will include 100 patients treated in a single institution between 2011 and 2016

Registry

clinicaltrials.gov

Start Date

January 1, 2018

End Date

January 2019

Last Updated

7 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

University Hospital, Strasbourg, France

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Adult patients
•Patients with breast cancer treated with neoadjuvant chemotherapy
•Patients with pre- and post-chemotherapy MRI
•Patients who have given their agreement to use their data for research purposes.

Exclusion Criteria

•Refusal to participate in the study

Outcomes

Primary Outcomes

Presence or absence of of pathologic enhancement of breast by MRI

Time Frame: 1 hour after the realization of the MRI

This work concerns 110 patients treated with neoadjuvant chemotherapy for breast cancer and having received a breast MRI in pre and post-chemiotherapy at the Hautepierre Hospital.